Prognostic Factors in Intensive Immunosuppressive Treatment of Chronic Progressive MS

  • O. R. Hommes
  • K. J. B. Lamers
  • P. Reekers
Conference paper


Since 1971 a short course of intensive immunosuppression has been induced in 86 chronic progressive multiple sclerosis (MS) patients [4].


Placebo Albumin Neurol Cyclophosphamide Stein 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bertrams J, Opperkuch W, Grosse-Wilde H, Wetzel B, Rittner Ch, Kuwert E, Schuppien W (1976) HLA linked C2 deficiency in multiple sclerosis. In: Dausset J, Svejgaard A (eds) HLA and Disease. INSERM, Paris, p 295Google Scholar
  2. 2.
    Dupont B, Oberfield SE, Smithwick EM, Lee TD, Levine LS (1977) Close genetic linkage between HLA and congenital adrenal hyperplasie (21-hydroxylase deficiency). Lancet II:1309–1312CrossRefGoogle Scholar
  3. 3.
    HLA and disease. Multiple sclerosis. In: Bodmer WF, Batchelor JR, Bodmer JG, Festenstein H, Morris PJ (eds) Histocompatibility testing 1977. Munksgaard, Copenhagen, pp 207–210Google Scholar
  4. 4.
    Hommes OR, Prick JJG, Lamers KJB (1975) Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 78:59–73PubMedCrossRefGoogle Scholar
  5. 5.
    Rose AS (1970) Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH versus placebo final report. Neurology (Minneap) 20:1–60Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • O. R. Hommes
  • K. J. B. Lamers
  • P. Reekers
    • 1
  1. 1.Department of Neurology and Laboratory of Transplantation Serology, Blood Transfusion ServiceRadboud University HospitalNijmegenThe Netherlands

Personalised recommendations